Ulrich Goldmann
Keine laufenden Positionen mehr
Profil
Dr. Ulrich Goldmann is Senior VP-Global Market Access & Medical Affairs at Synageva BioPharma Corp.
and Senior Vice President-Global Medical Affairs at Genzyme Corp.
He is on the Board of Directors at Grünenthal GmbH.
Dr. Goldmann was previously employed as a Director-Specialty Care Business Unit by Essex Pharma Development GmbH, Vice President & Global Head-Medical Affairs by Novartis Pharmaceuticals Corp., and VP-Global Scientific Research & Health Outcomes by Schering-Plough Corp.
He received his doctorate degree from Ludwig-Maximilians-Universität München.
Ehemalige bekannte Positionen von Ulrich Goldmann
| Unternehmen | Position | Ende |
|---|---|---|
| SYNAGEVA BIOPHARMA CORP | Technik-/Wissenschafts-/F&E-Leiter | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | - |
Essex Pharma Development GmbH
 Essex Pharma Development GmbH Miscellaneous Commercial ServicesCommercial Services Part of Nuvisan GmbH, Essex Pharma Development GmbH provides pharmaceutical analytics and development services. The company is based in Waltrop, Germany. Essex Pharma Development was acquired by Nuvisan GmbH from Merck & Co., Inc. on June 01, 2011. | Corporate Officer/Principal | - |
Ausbildung von Ulrich Goldmann
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Grünenthal GmbH
 Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany. | Health Technology |
Essex Pharma Development GmbH
Essex Pharma Development GmbH Miscellaneous Commercial ServicesCommercial Services Part of Nuvisan GmbH, Essex Pharma Development GmbH provides pharmaceutical analytics and development services. The company is based in Waltrop, Germany. Essex Pharma Development was acquired by Nuvisan GmbH from Merck & Co., Inc. on June 01, 2011. | Commercial Services |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
